21st Century Cures Act
Recorded December 21, 2016 | On-Demand Webinar
The 21st Century Cures Act—signed into law by the President on Tuesday, December 13, is sweeping bipartisan legislation intended to advance the research and development of new therapies and diagnostics and that makes substantial federal investments in a wide range of health care priorities. The Act’s changes to the Federal Food, Drug, and Cosmetic Act are significant, clarifying and creating new FDA authorities over drugs, including regenerative advanced therapies; medical devices, including certain health software; and combination products; as well as FDA’s administrative authorities. Join FDLI for an overview of the FDA-related sections of this new law while hearing directly from those intimately involved in the legislation.
Eva Temkin, Counselor, Office of the Chief Counsel, FDA
Wade Ackerman, Partner, Covington & Burling LLP
Marcy Busch, Counselor, Office of Chief Counsel, FDA
Moderated by Carla Cartwright, Director, Global Regulatory Policy & Intelligence, Janssen Pharmaceuticals Inc.
Wade Ackerman, Partner, Covington & Burling LLP
Marcy Busch, Counselor, Office of Chief Counsel, FDA
Moderated by Carla Cartwright, Director, Global Regulatory Policy & Intelligence, Janssen Pharmaceuticals Inc.
Get Access
$99
- +$100 for non-members
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Virtual Learning FAQ
On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.
On-demand content can be played back on most devices.
If you have concerns, please click the Test Your System link to determine your device's compatibility, as well as system requirements.
CLE credit is not currently available for pre-recorded sessions.
Related Content
